Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity

Collaboration Will Explore Potential of Other Assets to Address Obesity Epidemic

08-Aug-2011 - Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and ...

Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON

21-Oct-2010 - Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide extended-release for injectable suspension). In the ...

Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development

Orville Kolterman, MD Named Senior Vice President, Chief Medical Officer

03-Jun-2010 - Amylin Pharmaceuticals, Inc. announced that Christian Weyer, MD has been appointed Senior Vice President, Research and Development. Orville Kolterman, MD, has been named Senior Vice President, Chief Medical Officer. These leadership changes will strengthen the Company's focus on preparations for ...

BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes

03-Nov-2009 - Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA(R) (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to ...

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity

02-Nov-2009 - Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related ...

Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for Peptide Hybrid

Program will Focus on the Potential Treatment of Diabetes

14-Sep-2009 - Amylin Pharmaceuticals, Inc. and Biocon, Limited announced that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic ...

Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board

25-Aug-2009 - Amylin Pharmaceuticals, Inc. announced that its Board of Directors has elected Paulo F. Costa as Chairman of the Board, effective immediately. Mr. Costa was formerly President and Chief Executive Officer of Novartis U.S. Corporation, where he held several other executive positions, including ...

Amylin Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

13-Jul-2009 - Amylin Pharmaceuticals, Inc. announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, in overweight and obese ...

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

09-Jul-2009 - Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA). Exenatide once weekly is an investigational sustained release medication for ...

Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction

Changes will result in over $80 million reduction in 2009 cash expenditures

12-Nov-2008 - Amylin Pharmaceuticals, Inc. announced a corporate restructuring that will reduce its San Diego workforce by approximately 25 percent, or 340 employees, and reduce anticipated 2009 cash expenditures by more than $80 million. The restructuring and workforce reduction are part of the Company's ...